Literature DB >> 33334812

Time-Dependent Effects of Oral Contraceptive Use on Breast, Ovarian, and Endometrial Cancers.

Weronica E Ek1, Åsa Johansson2, Torgny Karlsson1, Therese Johansson1,3, Julia Höglund1.   

Abstract

Oral contraceptive use has been suggested to influence the risk of breast, ovarian, and endometrial cancer. The purpose of this study is to clarify the time-dependent effects between long-term oral contraceptive use and cancer risk. We performed an observational study in 256,661 women from UK Biobank, born between 1939 and 1970. Information on cancer diagnoses were collected from self-reported data and from national registers until March 2019. Cumulative risk of cancer over the timespan of the study, as measured by the OR, and instantaneous risk, as measured by the HR, were assessed using Logistic and Cox regression analyses, respectively. The odds were lower among ever users, compared with never users, for ovarian cancer [OR = 0.72; 95% confidence interval (CI), 0.65-0.81] and endometrial cancer (OR = 0.68; 95% CI, 0.62-0.75), an association that was stronger with longer use (P < 0.001). Increased odds were seen for breast cancer in women when limiting the follow-up to 55 years of age (OR = 1.10; 95% CI, 1.03-1.17), but not for the full timespan. We only found a higher HR for breast cancer in former users immediately (≤2 years) after discontinued oral contraceptive use (HR = 1.55; 95% CI, 1.06-2.28), whereas the protective association for ovarian and endometrial cancer remained significant up to 35 years after last use of oral contraceptives. Given the body of evidence presented in our study, we argue that oral contraceptives can dramatically reduce women's risk of ovarian and endometrial cancer, whereas their effect on lifetime risk of breast cancer is limited. SIGNIFICANCE: These results enable women and physicians to make more informed decisions considering oral contraceptive use, thus constituting an important step toward personalized medicine. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID: 33334812     DOI: 10.1158/0008-5472.CAN-20-2476

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.

Authors:  Frank G Lawton; Edward J Pavlik
Journal:  Diagnostics (Basel)       Date:  2022-03-24

2.  Aging accelerates while multiparity delays tumorigenesis in mouse models of high-grade serous carcinoma.

Authors:  Xiaoman Hou; Yali Zhai; Kevin Hu; Chia-Jen Liu; Aaron Udager; Celeste L Pearce; Eric R Fearon; Kathleen R Cho
Journal:  Gynecol Oncol       Date:  2022-04-09       Impact factor: 5.304

3.  An Update on Contraception in Polycystic Ovary Syndrome.

Authors:  Seda Hanife Oguz; Bulent Okan Yildiz
Journal:  Endocrinol Metab (Seoul)       Date:  2021-04-15

Review 4.  Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling.

Authors:  Ghada Mohammed; Noha A Mousa; Iman M Talaat; Haya Ibrahim; Maha Saber-Ayad
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-17       Impact factor: 5.555

5.  Clinical Value Analysis of Combined Vaginal Ultrasound, Magnetic Resonance Dispersion Weighted Imaging, and Multilayer Spiral CT in the Diagnosis of Endometrial Cancer Using Deep VGG-16 AdaBoost Hybrid Classifier.

Authors:  Xiaoyi Wang; Rong Zhang
Journal:  J Oncol       Date:  2022-04-26       Impact factor: 4.375

6.  Investigating the Effect of Estradiol Levels on the Risk of Breast, Endometrial, and Ovarian Cancer.

Authors:  Åsa Johansson; Daniel Schmitz; Julia Höglund; Fatemeh Hadizadeh; Torgny Karlsson; Weronica E Ek
Journal:  J Endocr Soc       Date:  2022-06-29

7.  Hormonal contraception and risk of breast cancer and breast cancer in situ among Swedish women 15-34 years of age: A nationwide register-based study.

Authors:  Jenny Niemeyer Hultstrand; Kristina Gemzell-Danielsson; Helena Kopp Kallner; Henrik Lindman; Per Wikman; Inger Sundström-Poromaa
Journal:  Lancet Reg Health Eur       Date:  2022-07-29

8.  BTN3A3 inhibits the proliferation, migration and invasion of ovarian cancer cells by regulating ERK1/2 phosphorylation.

Authors:  Sihan Chen; Zhangyun Li; Yanyan Wang; Shaohua Fan
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

9.  Serum Estradiol and 20 Site-Specific Cancers in Women: Mendelian Randomization Study.

Authors:  Susanna C Larsson; Siddhartha Kar; John R B Perry; Paul Carter; Mathew Vithayathil; Amy M Mason; Douglas F Easton; Stephen Burgess
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.